



Clinical trial results:

A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients.

Summary

EudraCT number	2011-004483-30
Trial protocol	BE DE ES AT PT GB IT
Global end of trial date	09 December 2014

Results information

Result version number	v1 (current)
This version publication date	05 June 2016
First version publication date	05 June 2016

Trial information

Trial identification

Sponsor protocol code	GS-US-236-0115
-----------------------	----------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01475838
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Gilead Sciences
Sponsor organisation address	333 Lakeside Drive, Foster City, CA, United States, 94404
Public contact	Clinical Trial Information Desk, Gilead Sciences International Ltd, +44 1223897 496, clinical.trials@gilead.com
Scientific contact	Clinical Trial Information Desk, Gilead Sciences International Ltd, +44 1223897 496, clinical.trials@gilead.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 December 2014
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	09 December 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the non-inferiority of Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF)) single tablet regimen (STR) relative to regimens consisting of a ritonavir-boosted protease inhibitor (PI/r) plus FTC/TDF in maintaining HIV-1 RNA < 50 copies/mL at Week 48 (Snapshot Analysis) in virologically suppressed, HIV 1 infected adults.

Protection of trial subjects:

The protocol and consent/assent forms were submitted by each investigator to a duly constituted Independent Ethics Committee (IEC) or Institutional Review Board (IRB) for review and approval before study initiation. All revisions to the consent/assent forms (if applicable) after initial IEC/IRB approval were submitted by the investigator to the IEC/IRB for review and approval before implementation in accordance with regulatory requirements.

This study was conducted in accordance with recognized international scientific and ethical standards, including but not limited to the International Conference on Harmonization guideline for Good Clinical Practice (ICH GCP) and the original principles embodied in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 November 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Portugal: 19
Country: Number of subjects enrolled	Spain: 50
Country: Number of subjects enrolled	United Kingdom: 15
Country: Number of subjects enrolled	Austria: 15
Country: Number of subjects enrolled	Belgium: 8
Country: Number of subjects enrolled	France: 54
Country: Number of subjects enrolled	Germany: 58
Country: Number of subjects enrolled	Italy: 61
Country: Number of subjects enrolled	United States: 125
Country: Number of subjects enrolled	Switzerland: 20
Country: Number of subjects enrolled	Canada: 8
Country: Number of subjects enrolled	Puerto Rico: 5
Worldwide total number of subjects	438
EEA total number of subjects	280

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	434
From 65 to 84 years	4
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants were enrolled at study sites in North America and Europe. The first participant was screened on 18 November 2011. The last study visit occurred on 09 December 2014

Pre-assignment

Screening details:

632 participants were screened.

Period 1

Period 1 title	Randomized Phase
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Stribild

Arm description:

Participants switched from their baseline treatment regimen to Stribild STR once daily for up to 96 weeks in the randomized phase, and may have continued to receive Stribild in the extension phase.

Arm type	Experimental
Investigational medicinal product name	Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Investigational medicinal product code	
Other name	Stribild®, EVG/COBI/FTC/TDF
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (150/150/200/300 mg) STR once daily

Arm title	PI+RTV+FTC/TDF
------------------	----------------

Arm description:

Participants stayed on their baseline treatment regimen consisting of a protease inhibitor (PI) (atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV)) boosted with ritonavir (RTV) plus emtricitabine (FTC)/TDF (200/300 mg) for up to 96 weeks in the randomized phase, and may have switched to Stribild in the extension phase.

Arm type	Active comparator
Investigational medicinal product name	Emtricitabine/tenofovir disoproxil fumarate
Investigational medicinal product code	
Other name	Truvada®, FTC/TDF
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

FTC/TDF (200/300 mg) administered according to prescribing information

Number of subjects in period 1 ^[1]	Stribild	PI+RTV+FTC/TDF
Started	293	140
Completed	263	109
Not completed	30	31
Withdrew Consent	10	14
Adverse event, non-fatal	6	1
Participant Noncompliance	1	5
Lost to Follow-up	3	4
Investigators Discretion	1	2
Pregnancy	-	1
Protocol Violation	9	4

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 5 participants who were enrolled but not treated are not included in the subject disposition table.

Period 2

Period 2 title	Extension Phase
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Stribild

Arm description:

Participants switched from their baseline treatment regimen to Stribild® STR once daily for up to 96 weeks in the randomized phase, and may have continued to receive Stribild in the extension phase.

Arm type	Experimental
Investigational medicinal product name	Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil fumarate
Investigational medicinal product code	
Other name	Stribild®; E/C/F/TDF
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil fumarate (150/150/200/300 mg) STR administered orally once daily

Arm title	PI+RTV+FTC/TDF
------------------	----------------

Arm description:

Participants stayed on their baseline treatment regimen consisting of a PI (ATV, DRV, FPV, LPV, or SQV) boosted with RTV plus FTC/TDF for up to 96 weeks in the randomized phase, and may have switched to Stribild in the extension phase.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	FTC/TDF
Investigational medicinal product code	
Other name	Truvada®
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

FTC/TDF (200/300 mg) administered according to prescribing information

Number of subjects in period 2^[2]	Stribild	PI+RTV+FTC/TDF
Started	42	20
Completed	41	20
Not completed	1	0
Participant Noncompliance	1	-

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Of those who completed the Randomized Phase (Stribild: n = 293; PI/RTV/FTC/TDF: n = 140), 42 participants randomized to Stribild and 20 participants randomized to PI/RTV/FTC/TDF entered the Extension Phase.

Baseline characteristics

Reporting groups

Reporting group title	Stribild
Reporting group description:	
Participants switched from their baseline treatment regimen to Stribild STR once daily for up to 96 weeks in the randomized phase, and may have continued to receive Stribild in the extension phase.	
Reporting group title	PI+RTV+FTC/TDF
Reporting group description:	
Participants stayed on their baseline treatment regimen consisting of a protease inhibitor (PI) (atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV)) boosted with ritonavir (RTV) plus emtricitabine (FTC)/TDF (200/300 mg) for up to 96 weeks in the randomized phase, and may have switched to Stribild in the extension phase.	

Reporting group values	Stribild	PI+RTV+FTC/TDF	Total
Number of subjects	293	140	433
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	41	41	
standard deviation	± 9.7	± 8.9	-
Gender categorical			
Units: Subjects			
Female	43	19	62
Male	250	121	371
Race			
Units: Subjects			
American Indian or Alaska Native	2	1	3
Asian	7	2	9
Black or African Heritage	43	20	63
White	234	113	347
Other	5	2	7
Not Permitted	2	2	4
Ethnicity			
Units: Subjects			
Hispanic or Latino	42	17	59
Non-Hispanic/Latino	249	123	372
Not Permitted	2	0	2
HIV-1 RNA Category			
Units: Subjects			
< 50 copies/mL	291	137	428
50 to < 200 copies/mL	2	2	4
200 to < 400 copies/mL	0	0	0
≥ 400 copies/mL	0	1	1
CD4+ Cell Count Category			
Units: Subjects			
≤ 50 cells/μL	0	0	0
51 to ≤ 200 cells/μL	9	6	15

201 to ≤ 350 cells/μL	37	14	51
351 to ≤ 500 cells/μL	69	26	95
> 500 cells/μL	178	94	272
HIV Disease Status			
Units: Subjects			
Asymptomatic	214	105	319
Symptomatic HIV Infections	38	17	55
AIDS	41	18	59
CD4+ Cell Count			
Units: cells/μL			
arithmetic mean	604	624	
standard deviation	± 274.6	± 269.9	-

End points

End points reporting groups

Reporting group title	Stribild
Reporting group description: Participants switched from their baseline treatment regimen to Stribild STR once daily for up to 96 weeks in the randomized phase, and may have continued to receive Stribild in the extension phase.	
Reporting group title	PI+RTV+FTC/TDF
Reporting group description: Participants stayed on their baseline treatment regimen consisting of a protease inhibitor (PI) (atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV)) boosted with ritonavir (RTV) plus emtricitabine (FTC)/TDF (200/300 mg) for up to 96 weeks in the randomized phase, and may have switched to Stribild in the extension phase.	
Reporting group title	Stribild
Reporting group description: Participants switched from their baseline treatment regimen to Stribild® STR once daily for up to 96 weeks in the randomized phase, and may have continued to receive Stribild in the extension phase.	
Reporting group title	PI+RTV+FTC/TDF
Reporting group description: Participants stayed on their baseline treatment regimen consisting of a PI (ATV, DRV, FPV, LPV, or SQV) boosted with RTV plus FTC/TDF for up to 96 weeks in the randomized phase, and may have switched to Stribild in the extension phase.	

Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48

End point title	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
End point description: The FDA-defined Snapshot algorithm was used, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time.	
End point type	Primary
End point timeframe: Week 48	

End point values	Stribild	PI+RTV+FTC/TDF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	290	139		
Units: Percentage of participants				
number (not applicable)	93.8	87.1		

Statistical analyses

Statistical analysis title	Difference in proportions
Statistical analysis description: The null hypothesis was that the Stribild group was at least 12% worse than the PI+RTV +FTC/TDF group with respect to the percentage of participants maintaining HIV-1 RNA < 50 copies/mL at Week 48. The alternative hypothesis was that the Stribild group was less than 12% worse than the	

PI+RTV+FTC/TDF group.

Comparison groups	Stribild v PI+RTV+FTC/TDF
Number of subjects included in analysis	429
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[1]
P-value	= 0.025
Method	Fisher exact
Parameter estimate	Difference in proportions
Point estimate	6.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.4
upper limit	13.7

Notes:

[1] - The 95% confidence interval (CI) for the difference was from unconditional exact method using 2 inverted 1-sided tests with the standardized statistic using StatXact.

Secondary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96

End point title	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96
-----------------	---

End point description:

The FDA-defined Snapshot algorithm was used, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 96

End point values	Stribild	PI+RTV+FTC/TDF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	290	139		
Units: Percentage of Participants				
number (not applicable)	86.9	69.8		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in CD4+ Cell Count at Week 48

End point title	Change From Baseline in CD4+ Cell Count at Week 48
-----------------	--

End point description:

Analysis Population Description: Participants in the Full Analysis Set with available data were analyzed; the missing-equals-excluded approach where participants with missing data were excluded from the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline; Week 48

End point values	Stribild	PI+RTV+FTC/T DF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	270	120		
Units: cells/ μ L				
arithmetic mean (standard deviation)	40 (\pm 169.5)	32 (\pm 166.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in CD4+ Cell Count at Week 96

End point title	Change From Baseline in CD4+ Cell Count at Week 96
End point description: Participants in the Full Analysis Set with available data while on study drug were analyzed; the missing-equals-excluded approach where participants with missing data were excluded from the analysis.	
End point type	Secondary
End point timeframe: Baseline; Week 96	

End point values	Stribild	PI+RTV+FTC/T DF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	255	104		
Units: cells/ μ L				
arithmetic mean (standard deviation)	61 (\pm 196.5)	71 (\pm 173.4)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline through end of study drug treatment (average exposure = 88 weeks) plus 30 days

Adverse event reporting additional description:

Safety Analysis Set: participants were randomized and received at least 1 dose of study drug

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.1
--------------------	------

Reporting groups

Reporting group title	Stribild
-----------------------	----------

Reporting group description:

Adverse events for this reporting group include those occurring in participants receiving Stribild in the randomized phase.

Participants switched from their baseline treatment regimen to Stribild STR once daily for up to 96 weeks in the randomized phase, and may have continued to receive Stribild in the extension phase.

Reporting group title	PI+RTV+FTC/TDF
-----------------------	----------------

Reporting group description:

Adverse events for this reporting group include those occurring in participants receiving PI+RTV+FTC/TDF in the randomized phase.

Participants stayed on their baseline treatment regimen consisting of a PI (ATV, DRV, FPV, LPV, or SQV) boosted with RTV plus FTC/TDF for up to 96 weeks in the randomized phase, and may have switched to Stribild in the extension phase.

Reporting group title	All Stribild
-----------------------	--------------

Reporting group description:

Adverse events for this reporting group include those occurring in participants while receiving Stribild in the randomized and extension phases.

Serious adverse events	Stribild	PI+RTV+FTC/TDF	All Stribild
Total subjects affected by serious adverse events			
subjects affected / exposed	24 / 293 (8.19%)	11 / 140 (7.86%)	24 / 313 (7.67%)
number of deaths (all causes)	0	1	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Hodgkin's disease			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive ductal breast carcinoma			

subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transitional cell carcinoma			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial carcinoma			
subjects affected / exposed	0 / 293 (0.00%)	1 / 140 (0.71%)	0 / 313 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Metastases to liver			
subjects affected / exposed	0 / 293 (0.00%)	1 / 140 (0.71%)	0 / 313 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Arteriosclerosis			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Drug withdrawal syndrome			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Benign prostatic hyperplasia			

subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Alcohol withdrawal syndrome			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Major depression			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychotic disorder			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide Attempt			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anxiety			
subjects affected / exposed	0 / 293 (0.00%)	1 / 140 (0.71%)	0 / 313 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bipolar I disorder			
subjects affected / exposed	0 / 293 (0.00%)	1 / 140 (0.71%)	0 / 313 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug abuse			

subjects affected / exposed	0 / 293 (0.00%)	1 / 140 (0.71%)	0 / 313 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Alcohol poisoning			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radius fracture			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound			
subjects affected / exposed	0 / 293 (0.00%)	1 / 140 (0.71%)	0 / 313 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 293 (0.00%)	1 / 140 (0.71%)	0 / 313 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Eye disorders			
Visual acuity reduced			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric haemorrhage			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Goitre			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthritis reactive			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myalgia			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			

subjects affected / exposed	0 / 293 (0.00%)	1 / 140 (0.71%)	0 / 313 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	2 / 293 (0.68%)	0 / 140 (0.00%)	2 / 313 (0.64%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	1 / 293 (0.34%)	1 / 140 (0.71%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 293 (0.34%)	1 / 140 (0.71%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Penile abscess			
subjects affected / exposed	1 / 293 (0.34%)	0 / 140 (0.00%)	1 / 313 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			

subjects affected / exposed	0 / 293 (0.00%)	1 / 140 (0.71%)	0 / 313 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 293 (0.00%)	1 / 140 (0.71%)	0 / 313 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal abscess			
subjects affected / exposed	0 / 293 (0.00%)	1 / 140 (0.71%)	0 / 313 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Stribild	PI+RTV+FTC/TDF	All Stribild
Total subjects affected by non-serious adverse events			
subjects affected / exposed	169 / 293 (57.68%)	67 / 140 (47.86%)	169 / 313 (53.99%)
Nervous system disorders			
Headache			
subjects affected / exposed	24 / 293 (8.19%)	10 / 140 (7.14%)	24 / 313 (7.67%)
occurrences (all)	26	10	26
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	27 / 293 (9.22%)	11 / 140 (7.86%)	27 / 313 (8.63%)
occurrences (all)	28	11	28
Nausea			
subjects affected / exposed	22 / 293 (7.51%)	5 / 140 (3.57%)	22 / 313 (7.03%)
occurrences (all)	22	5	22
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	20 / 293 (6.83%)	6 / 140 (4.29%)	20 / 313 (6.39%)
occurrences (all)	23	6	23
Psychiatric disorders			
Depression			

subjects affected / exposed occurrences (all)	18 / 293 (6.14%) 18	9 / 140 (6.43%) 9	18 / 313 (5.75%) 18
Insomnia subjects affected / exposed occurrences (all)	13 / 293 (4.44%) 14	8 / 140 (5.71%) 8	13 / 313 (4.15%) 14
Anxiety subjects affected / exposed occurrences (all)	19 / 293 (6.48%) 19	5 / 140 (3.57%) 5	20 / 313 (6.39%) 20
Musculoskeletal and connective tissue disorders			
Back pain subjects affected / exposed occurrences (all)	24 / 293 (8.19%) 26	4 / 140 (2.86%) 4	24 / 313 (7.67%) 26
Arthralgia subjects affected / exposed occurrences (all)	15 / 293 (5.12%) 15	4 / 140 (2.86%) 4	15 / 313 (4.79%) 16
Infections and infestations			
Nasopharyngitis subjects affected / exposed occurrences (all)	39 / 293 (13.31%) 49	20 / 140 (14.29%) 24	39 / 313 (12.46%) 49
Upper respiratory tract inflammation subjects affected / exposed occurrences (all)	29 / 293 (9.90%) 35	8 / 140 (5.71%) 11	29 / 313 (9.27%) 35
Syphilis subjects affected / exposed occurrences (all)	20 / 293 (6.83%) 24	6 / 140 (4.29%) 6	20 / 313 (6.39%) 24
Sinusitis subjects affected / exposed occurrences (all)	15 / 293 (5.12%) 17	6 / 140 (4.29%) 7	16 / 313 (5.11%) 18
Gastroenteritis subjects affected / exposed occurrences (all)	11 / 293 (3.75%) 12	7 / 140 (5.00%) 7	11 / 313 (3.51%) 13
Pharyngitis subjects affected / exposed occurrences (all)	16 / 293 (5.46%) 16	7 / 140 (5.00%) 7	16 / 313 (5.11%) 16

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
21 December 2011	<ul style="list-style-type: none">Extended the study from 48 to 96 weeks and removed the switch to STB at Week 48 for subjects in Treatment Group 2 based on feedback from the US Food and Drug Administration (FDA); updated Study Schema and Study ProceduresUpdated secondary study objectives based on feedback from the US FDAClarified and updated the inclusion and exclusion criteriaUpdated the Table of Disallowed and Discouraged Medications to reflect draft STB label
27 June 2012	<ul style="list-style-type: none">Updated inclusion criteria to change estimated glomerular filtration rate (eGFR) entry criteria from ≥ 90 mL/min to ≥ 70 mL/min and to clarify that subjects could be rescreened with approval from the medical monitorUpdated the screening visit procedures to align with the directive of Gilead's DSPH groupUpdated the overdose, safety, and pregnancy reporting requirementsUpdated the definitions of childbearing potential and postmenopausal statusUpdated the new contact information for DSPH and removed requirement to email safety event reports due to restrictive data privacy laws in some countriesUpdated Section 7.4 to align with the new CT3 guidanceUpdated Study Procedures Table footnotes

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

There were no limitations affecting the analysis or results.

Notes: